- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07534761
CHIRURGIE MINIMALEMENT INVASIVE POUR LES HÉMORROÏDES DE GRADE III
Étude observationnelle prospective pour évaluer la reproductibilité de la chirurgie mini-invasive dans l'hémorroïdectomie par excision fermée : Phase 2A du cadre I DEAL
Hemorrhoids are vascular-elastic structures of the anal canal that contribute to continence. Their enlargement and descent lead to symptoms such as rectal bleeding and the sensation of anal swelling, known as hemorrhoidal syndrome. In advanced cases (Goligher Grade III-IV), surgery is the only effective treatment. Closed excisional hemorrhoidectomy (CEH), based on the Ferguson technique, is one of the standard procedures. Although effective in the long term, it causes severe postoperative pain. Minimally invasive surgery (MIS) employs enhanced visualization devices to improve surgical precision and reduce tissue damage. While widely used in specialties with small surgical fields, it has not yet been explored in anal surgery. Its advantages include reduced tissue injury and improved healing, although it presents a learning curve and an initially longer surgical time. The IDEAL framework evaluates surgical innovations in five stages: Idea, Development, Exploration, Evaluation, and Long-Term Study. The IDEAL phase 2a is aimed at the optimization and technical definition of surgical innovation with a focus on continuous improvement based on real clinical practice, laying the foundation for broader and more rigorous subsequent studies.
Since no previous studies on the application of MIS in CEH have been found, the investigators propose a study within Stage 2A of the IDEAL model to assess the reproducibility of this technique. The investigators believe its incorporation into closed excisional hemorrhoidectomy could result in less postoperative pain and faster patient recovery.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ignacio Fernandez-Hurtado, Colorectal Surgeon
- Numéro de téléphone: 2134 +34 871202000
- E-mail: ifernandez@hsll.es
Lieux d'étude
-
-
Balearic Islands
-
Palma, Balearic Islands, Espagne, 07190
- Recrutement
- Hospital Son Llatzer
-
Contact:
- Ignacio Fernandez-Hurtado, Colorectal Surgeon
- Numéro de téléphone: 2134 +34 871 202000
- E-mail: ifernandez@hsll.es
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients attending the Surgery Department of our Hospital
La description
Inclusion Criteria:
- Age over 18 years
- Grade III/IV hemorrhoids
- Indication for CEH surgery
- Signed written informed consent
Exclusion Criteria:
- Acute hemorrhoidal disease (thrombosis)
- Previous hemorrhoid surgery
- Coexistence of anal fissure
- Coexistence of perianal fistula
- Coexistence of rectal or anal prolapse
- Active inflammatory bowel disease
- Active anal or colorectal cancer
- Language barrier or difficulty in oral and/or written comprehension
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: CASE_ONLY
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Grade III / IV hemorrhoids
Patients with symptomatic grade III/IV hemorrhoids who consent to surgical intervention |
The investigators propose applying minimally invasive surgery in closed excisional hemorrhoidectomy (CEH) , the most effective technique for treating advanced hemorrhoidal disease. The investigators believe this approach will reduce postoperative pain and improve recovery while maintaining the excellent outcomes of CEH. The investigator's hypothesis is based on the reduced tissue trauma and increased precision provided by minimally invasive surgery. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Technical Reproducibility of Surgery
Délai: 30 postoperative days
|
ince no studies using this approach were found in the literature, the investigators propose a study to assess the reproducibility of implementing this technique following the guidelines of the IDEAL framework. In this study, the investigators propose Stage 2A. The measurement tool will be the systematic documentation of technical modifications. |
30 postoperative days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Adverse events in treated patients
Délai: 30 postoperative days
|
Collect the adverse effects that occur during the operative period and within the first 30 postoperative days. Filter those attributable to the use of the minimally invasive approach. Analyze the causes and the technical steps that should be performed or omitted to avoid them. As measurement tools, the Clavien-Dindo scale and the Comprehensive Complication Index (CCI) will be used. The CCI is an index that uses the Clavien-Dindo scale and is calculated with a mathematical formula available at www.assessurgery.com |
30 postoperative days
|
|
Postoperative pain
Délai: The first 14 postoperative days
|
Postoperative pain will be evaluated using the Visual Analogue Scale (VAS), a validated tool ranging from 0 (no pain) to 10 (worst imaginable pain). Patients will self-assess their baseline pain and pain following defecation at predefined intervals: postoperative days 4, 7, and 14. |
The first 14 postoperative days
|
|
Hemorrhoidal disease symptom score
Délai: one postoperative year
|
A score that defines the frecuency of pain, pruritus, bleeding, soiling and prolapse. Score 0 to 20. Higher scores mean a worse outcome. |
one postoperative year
|
|
Short Health Scale in hemorrhoidal disease
Délai: One year postoperative
|
A subjective scale which defines symptom intensity, the patient's worrying and the role in impairment of daily activity. Score 4 to 28. Higher scores mean a worse outcome |
One year postoperative
|
|
Total number of postoperative analgesics
Délai: 14 postoperative days
|
The total number of analgesic doses taken by the patient during the first 14 postoperative days will be recorded as a numeric variable |
14 postoperative days
|
|
Clinical Failure Rate
Délai: one year postoperative
|
Clinical failure rate (CFR) is defined by the difference in haemorrhoidal symptoms according to Haemorrhoidal Disease Symptom Score and haemorrhoidal disease-related quality of life according to Short Health Scale adapted for Haemorrhoidal Disease comparing baseline and 1-year values. This difference was calculated using the following formula: (baseline Haemorrhoidal Disease Symptom Score - postoperative Haemorrhoidal Disease Symptom Score )/ baseline Haemorrhoidal Disease Symptom Score × 100. The change in quality of life related to haemorrhoidal disease was calculated using the following formula: (baseline Short Health Scale adapted for Haemorrhoidal Disease - postoperative Short Health Scale adapted for Haemorrhoidal Disease.)/baseline Short Health Scale adapted for Haemorrhoidal Disease. × 100. CFR was positive when both criteria showed a ≤50% difference. |
one year postoperative
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- HEM CLOSE IDEAL 2A
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .